New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
NCT ID NCT06153251
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called BMS-986453 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins on cancer cells, to attack the disease. The study will enroll 187 participants to find the best dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMS-986453 (a type of CAR T cell therapy that targets two proteins on cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for people with multiple myeloma that has not responded to other therapies.
- What could go wrong
- This is an early Phase 1 trial, so safety and effectiveness are not yet proven. Side effects may be serious, and the therapy may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
Contact Phone: •••-•••-••••
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
RECRUITINGSalamanca, 37007, Spain
Contact Phone: •••-•••-••••
-
Hôpital Saint-Louis
RECRUITINGParis, 75010, France
Contact Phone: •••-•••-••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-••••
-
Local Institution - 0008
NOT_YET_RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-••••
-
Stanford University Medical Center
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-••••
-
Swedish Medical Center
RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-••••
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
UCSF Helen Diller Medical Center at Parnassus Heights
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-••••
-
Universitaetsklinikum Heidelberg
RECRUITINGHeidelberg, D-69120, Germany
Contact Phone: •••-•••-••••
-
Universitaetsklinikum Koeln
RECRUITINGCologne, 50937, Germany
Contact Phone: •••-•••-••••
-
Universitaetsklinikum Wuerzburg
RECRUITINGWürzburg, 97080, Germany
Contact Phone: •••-•••-••••
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-••••
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.